Needham analyst Mike Matson reiterated a Buy rating and $4.25 price target on OncoCyte Corp (NASDAQ: OCX).The analyst commented: "OCX's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE